Johnson Kenneth P, Due Deborah L
University of Maryland, Baltimore, MD, USA.
Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):205-14. doi: 10.1586/erp.09.20.
Relapsing-remitting multiple sclerosis is a chronic, progressive disorder marked by repeated exacerbations that lead to increases in neurological disability. Glatiramer acetate and the IFN-betas are recommended as first-line agents for relapsing-remitting multiple sclerosis owing to their potential to reduce frequency and severity of relapses, decrease development of new brain lesions and delay permanent disability. After three decades of study, the preponderance of the evidence suggests that the efficacy of glatiramer acetate is similar to the IFN-betas and new data collected in more naturalistic settings suggest that it may provide improved quality of life, increased productivity and cost-effectiveness. This article will review this evidence including data from very recent head-to-head clinical trials and pharmacoeconomic analyses of cost-effectiveness.
复发缓解型多发性硬化症是一种慢性进行性疾病，其特征为反复出现病情加重，导致神经功能障碍加剧。醋酸格拉替雷和β-干扰素被推荐作为复发缓解型多发性硬化症的一线治疗药物，因为它们有可能降低复发的频率和严重程度，减少新脑损伤的发生，并延缓永久性残疾的出现。经过三十年的研究，大量证据表明醋酸格拉替雷的疗效与β-干扰素相似，在更接近实际情况的环境中收集的新数据表明，它可能会改善生活质量、提高生产力并具有成本效益。本文将回顾这一证据，包括来自最近的直接比较临床试验的数据以及成本效益的药物经济学分析。
